Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.00
Change (%)0.00 (0.00%)
Volume0
Data as of 05/22/17 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
05/17/17Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
05/15/17Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
05/12/17Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
05/08/17Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
Upcoming EventsMore >>
DateTitle
06/06/17
through
06/09/17
Eiger BioPharmaceuticals at the Jefferies 2017 Global Healthcare Conference
08/15/17
through
08/16/17
Eiger BioPharmaceuticals at the Wedbush PacGrow Healthcare Conference
LocationNew York, NY
09/10/17
through
09/12/17
Eiger BioPharmaceuticals at the Rodman & Renshaw 19th Annual Global Investment Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.